

## SCIENTIFIC PROGRAMME

- 08.15 – 08.30 Registration
- 08.30 – 08.40 Opening  
*Dra. García* (Hospital U. Reina Sofia Manager) and *Dr. Briceño* (Head of Surgery, Hospital U. Reina Sofia)
- 08.40 – 09.00 Welcome  
*Prof. Rufian Peña* (Hospital U. Reina Sofia) and *Dra. Flatmark* (Oslo University Hospital)

### Session 1: Diagnosis of PMP. Chairs: Dr Mohamed / Dra. Casado

---

- 09.00 – 09.15 **Diagnosis of PMP – Pathology**  
How is PMP diagnosed? How is it classified, and why is it important to get the diagnosis and classification correct?  
*Dr. Carr* (Hampshire Hospitals NHS Trust)
- 09.20 – 09.30 **Diagnosis of PMP – Radiology**  
How are radiology and nuclear diagnostic techniques used to diagnose and classify PMP?  
*Dra. Martin* (Hospital U. Reina Sofia)
- 09.30 – 09.40 **Diagnosis of PMP – Radiology II**  
Radiological evaluation of the respectability of PMP  
*Dr. Thrower* (Peritoneal Malignancy Institut)
- 09.45 – 09.55 **Diagnosis of PMP – Molecular analysis**  
*Dr. Romero Ruiz* (IMIBIC Research Institut)

### Session 2: EuroPMP. Chairs: Dr. Barrios / Dr. Arjona

---

- 10.00 – 10.15 **The EuroPMP COST Action**  
How the COST Action model works, who is involved and how is it managed. STSMs and other opportunities for ECI researchers.  
*Dra. Flatmark* (Oslo University Hospital)
- 10.20 – 10.35 **Standardising protocols - Why is it important?**  
A short look into why protocol standardisation is important (comparability, sharing of data, sample sharing, etc.) and what the EuroPMP Action is doing to try to standardise protocols.  
*Dr. Carr* (Hampshire Hospitals NHS)
- 10.40 – 11.00 Coffee Break
- 11.00 – 11.15 **Standards of Care Across Europe**  
What is the standard of care around Europe right now? How can EuroPMP work to improve the care and outcomes for PMP patients?  
*Dr. Mohamed Faheez* (Peritoneal Malignancy Institute)
- 11.20 – 11.35 **Scientific Communication: What's the point?**  
Why is it important to get the word out not just about major research findings, but also about treatment methods and care? How do we target the various levels of people so that everyone is able to get what they need, from a top scientist to a newly diagnosed patient? How is the EuroPMP COST Action helping to improve awareness of PMP in Europe?  
*Dr. Bartos* (Regional Institute of Gastroenterology and Hepatology)
-

---

**Session 3: Selected topics from PMP experimental research Chairs: Dr. Deraco / Dra. Rodriguez**

---

- 11.40 – 11.55      Topic 1 How the different experimental models of PMP help us in its molecular characterization and treatment?  
*Dr. Romero Ruiz (IMIBIC Research Institut)*
- 12.00 – 12.15      Topic 2 Targeting therapies, a necessary weapon in the PMP management.  
*Dr. Shigeki Kusamura (Fondazione IRCCS Istituto Nazionale Tumori di Milano)*

---

**Session 4: Early Career Investigators' Session Chairs: Dra. Flatmark / Dr. Romero**

---

- 12.20 – 12.30      Bromelain combined with N-acetyl-cysteine as mucolytic agent to treat extensive and/or recurrent pseudomyxoma peritonei  
*Dra. Kepenekian (France)*
- 12.35 – 12.45      Can the mucolytic drug bromelain and acetylcysteine be applied as pressurized intraperitoneal aerosol (PIPAC)?  
*Dr. Sautkin (Germany)*
- 12.50 – 13.00      Hydroxamic acid analogs of Vorinostat as new potent cytotoxic agents  
*Dra. Mantzourani (Greece)*
- 13.05 – 13.15      Novel therapeutic targets for pseudomyxoma peritonei  
*Dr. Lund-Andersen (Norway)*
- 13.20 – 13.30      Molecular characterization of pseudomyxoma peritonei and development of biomarkers and target therapies in a mouse model with human xenograft  
*Dra. Rufian (Spain)*
- 13.30 – 14.30      Poster viewing and networking
- 14.30 – 15.30      Lunch

---

**Session 5: Surgical Treatment of PMP Chairs: Dr. Bartos / Dr. Sanchez**

---

- 15.30 – 16.30      **Treatment of PMP – surgery**
- 15.30 – 15.45      CRS-HIPEC  
*Dr. Pedro Barrios (Consorti, Sanitari Integral - CCSI)*
- 15.50 – 16.05      Role of minimally invasive approaches, is there a role for PIPAC?  
*Dr. Arjona Sanchez (H.U. Reina Sofia)*
- 16.10 – 16.25      Choosing the best drug for HIPEC in PMP  
*Dr. Marcello Deraco (Fondazione IRCCS Istituto Nazionale Tumori di Milano)*
- 16.30 – 16.45      Unexpected appendiceal tumors  
*Dr. Shigeki Kusamura (Fondazione IRCCS Istituto Nazionale Tumori di Milano)*
- 16.50 – 17.20      **Treatment of PMP after primary surgical management of PMP**
- 16.50 – 17.00      Systemic Treatment of PMP  
*Dr. Manuel Valladares (H.U. Reina Sofia)*
- 17.05 – 17.20      What happens when primary treatment fails?  
*Dr. Marcello Deraco (Fondazione IRCCS Istituto Nazionale Tumori di Milano)*
- 17.25 – 17.40      **Future directions in PMP**  
*Dr. Mohamed Faheez (Peritoneal Malignancy Institute)*
- 17.45 – 18.00      **Closing and take-home-messages**  
*Dr. Arjona-Sanchez (H.U. Reina Sofia)*

**EuroPMP**  
International  
Workshop on  
Pseudomyxoma  
Peritonei  
with Early Career  
Investigators Workshop  
**Córdoba 4<sup>th</sup> October 2019**

Endorsedy by:

